| Not Yet Recruiting | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) NCT07166549 | University Hospital, Basel, Switzerland | Phase 1 |
| Recruiting | A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Par NCT07422337 | Arkansas Children's Hospital Research Institute | — |
| Not Yet Recruiting | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL a NCT05779930 | Nationwide Children's Hospital | EARLY_Phase 1 |
| Recruiting | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies NCT06208735 | British Columbia Cancer Agency | Phase 1 |
| Recruiting | Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors NCT06662227 | Wondercel Biotech (ShenZhen) | EARLY_Phase 1 |
| Unknown | A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies NCT05932173 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 / Phase 2 |
| Recruiting | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or R NCT05442515 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies NCT05570188 | Kunming Hope of Health Hospital | Phase 1 / Phase 2 |
| Unknown | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies NCT05487651 | Athenex, Inc. | Phase 1 |
| Completed | Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Chil NCT05095155 | Asfendiyarov Kazakh National Medical University | — |
| Unknown | Induced-T Cell Like NK Cells for B Cell Malignancies NCT04747093 | Nanfang Hospital, Southern Medical University | Phase 1 / Phase 2 |
| Unknown | Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT NCT04516551 | Xinqiao Hospital of Chongqing | Phase 1 |
| Completed | CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies NCT04605666 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Completed | CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients NCT04260945 | Hebei Yanda Ludaopei Hospital | Phase 1 |
| Unknown | CAR-T Immunotherapy Targeting CD19- ALL NCT04016129 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Unknown | Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies NCT03881774 | Henan Cancer Hospital | Phase 1 |
| Unknown | CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies NCT04156178 | iCell Gene Therapeutics | EARLY_Phase 1 |
| Completed | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD NCT03448393 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies NCT04156243 | iCell Gene Therapeutics | EARLY_Phase 1 |
| Unknown | A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy fo NCT03398967 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Withdrawn | Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies NCT03098355 | Zhujiang Hospital | Phase 1 / Phase 2 |
| Unknown | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tu NCT03302403 | Kang YU | N/A |
| Unknown | A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Rel NCT03463928 | Chinese PLA General Hospital | Phase 1 |
| Completed | CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy NCT03068416 | Uppsala University | Phase 2 |
| Unknown | A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma NCT03166878 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Unknown | A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia NCT03383952 | Immune Cell, Inc. | Phase 1 |
| Unknown | CAR T Cells for Refractory B Cell Malignancy NCT02963038 | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 / Phase 2 |
| Completed | CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. NCT02132624 | Uppsala University | Phase 1 / Phase 2 |
| Active Not Recruiting | A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Ly NCT01683279 | Seattle Children's Hospital | Phase 1 |
| Completed | Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Ly NCT01626495 | University of Pennsylvania | Phase 1 / Phase 2 |
| Completed | Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma NCT00849654 | Pharmacyclics LLC. | Phase 1 |
| Completed | Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia NCT00230282 | Steven E. Coutre | Phase 2 |